Research programme: immune-mediated disease therapeutics - Sanofi/UCB
Latest Information Update: 28 Jul 2018
At a glance
- Originator Sanofi; UCB
- Class Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Immunological disorders
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for research development in Immunological-disorders in Belgium
- 28 Jul 2018 No recent reports of development identified for research development in Immunological-disorders in France
- 12 Mar 2014 Early research in Immunological disorders in France and Belgium (unspecified route)